Medtronic PLC $MDT Shares Sold by 17 Capital Partners LLC

17 Capital Partners LLC lessened its position in shares of Medtronic PLC (NYSE:MDT) by 11.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,294 shares of the medical technology company’s stock after selling 1,172 shares during the quarter. 17 Capital Partners LLC’s holdings in Medtronic were worth $810,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in MDT. 1248 Management LLC acquired a new position in Medtronic during the first quarter worth about $26,000. Twin Tree Management LP acquired a new stake in shares of Medtronic in the first quarter valued at approximately $29,000. Activest Wealth Management increased its stake in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares in the last quarter. Investment Management Corp VA ADV raised its position in shares of Medtronic by 144.2% during the 1st quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 238 shares during the last quarter. Finally, GFG Capital LLC purchased a new stake in Medtronic in the 2nd quarter valued at approximately $36,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on MDT. Leerink Partners set a $120.00 price target on Medtronic and gave the stock an “outperform” rating in a research report on Wednesday. Cowen reiterated a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Robert W. Baird boosted their target price on shares of Medtronic from $103.00 to $109.00 and gave the company a “neutral” rating in a research note on Wednesday. Wells Fargo & Company upped their target price on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $108.50.

Insider Buying and Selling at Medtronic

In other Medtronic news, Director William R. Jellison purchased 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the transaction, the director owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.26% of the stock is owned by corporate insiders.

Medtronic Stock Performance

Shares of NYSE:MDT opened at $100.12 on Thursday. The business has a 50-day moving average of $94.80 and a two-hundred day moving average of $90.70. The firm has a market capitalization of $128.42 billion, a PE ratio of 27.58, a P/E/G ratio of 2.42 and a beta of 0.77. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $102.59.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the previous year, the business earned $1.26 EPS. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.